Backer, US
Brian Backer, Allen, TX US
Patent application number | Description | Published |
---|---|---|
20140267917 | ULTRA LOW LATENCY VIDEO FUSION - Methods and systems for processing video are provided. A method includes receiving first and second video signals and generating a mask as a function of the second video signal, the mask having mask and peripheral areas. The method displays the first video signal in the peripheral area and processes the second video signal in the mask area. The method displays the processed second video signal in the mask area. A system includes a processor and a memory with stored instructions, that, when executed by the processor, cause to processor to receive first and second video signals and generate a mask as a function of the second video signal, wherein the mask has a mask area and a peripheral area. The system displays the first video signal in the peripheral area, processes the second video signal in the mask area, and displays the processed second video signal in the mask area. | 09-18-2014 |
Brian Backer, Melbourne, FL US
Patent application number | Description | Published |
---|---|---|
20150130950 | METHOD AND SYSTEM FOR INTEGRATED OPTICAL SYSTEMS - A method of operating optical systems includes forming a stitched image of a field of regard using a first optical device. The stitched image of the field of regard comprises a plurality of sub-images associated with a first field of view. The method also includes receiving an image of a second field of view from a second optical device and determining a location of the image of the second field of view in the stitched image. The method further includes communicating an indicator to the second optical device. The indicator is to the location of the image of the second field of view in the stitched image. | 05-14-2015 |
Carl L. Backer, Chicago, IL US
Patent application number | Description | Published |
---|---|---|
20090299330 | Cellular Delivery Device - A cellular delivery device comprising a cellular carrier and an insertion device is provided. The cellular carrier includes at least one elongate strand of biocompatible material with a distal end and a proximal end. A stop member is connected to the proximal end of the elongate strand. The insertion device includes a needle attached to a hollow tubular body. The hollow tubular body is sized to receive the cellular carrier such that at least a portion of the elongate strand may be located within the hollow tubular body and the stop member protrudes from the proximal end of the hollow tubular body. | 12-03-2009 |
Cynthia Backer, High Ridge, MO US
Patent application number | Description | Published |
---|---|---|
20140100913 | BUSINESS CONTINUITY AND RESPONSE PLAN MANAGEMENT - Embodiments described herein include are directed to managing response plans of an enterprise. Business recovery plans, system recovery plans, and emergency management plans for the enterprise are identified, where the business recovery plans relating to business aspects of the enterprise, the system recovery plans relating to technology aspects of the enterprise, and the emergency management plans relating to emergencies affecting the enterprise. The business recovery plans, system recovery plans, and emergency management plans are evaluated and plan metrics for the business recovery plans, system recovery plans, and emergency management plans are calculated independently and separately from each other. The plan metrics are calculated in response to the evaluation of the business recovery plans, the system recovery plans, and the emergency management plans. A readiness of the business recovery plans, the system recovery plans, and the emergency management plans is determined based on the evaluation. | 04-10-2014 |
Gerald P. Backer, Southfield, MI US
Patent application number | Description | Published |
---|---|---|
20140057140 | Reduction of Water Transfer Across Membrane - A method of operating a redox flow battery includes a step of observing a difference in relative volume between the anolyte fluid volume and the catholyte fluid volume. The ionic molality of anolyte fluid is increased if the relative volume of the anolyte fluid decreases. A redox flow battery having balanced anolyte and catholyte initial ionic molalities is also provided. | 02-27-2014 |
20150244008 | FLOW CELL WITH SHUNT CURRENT COUNTER ELECTRODE - Counter electrodes are used within the context of a flow cell to attract shunt current depositions during operation. The counter electrodes may be electrically connected with an anode of the flow cell to attract the depositions and then electrically connected with a cathode of the flow cell to remove the depositions. | 08-27-2015 |
Gerald Peter Backer, Southfield, MI US
Patent application number | Description | Published |
---|---|---|
20110144788 | Method for simulating casting defects and microstructures of castings - Systems for predicting casting defects and microstructure in suppliers/vendors' castings for part/system durability analysis without knowing the details of the casting layout and casting gating and riser design as well as casting process parameters are provided. The systems involve the use of an integrated pore growth and interdendritic flow model. Methods of predicting casting defects and microstructures of a part without knowing the details of the casting layout and casting gating and riser design as well as casting process parameters and articles of manufacture are also provided. | 06-16-2011 |
Jerry Backer, Coon Rapids, MN US
Patent application number | Description | Published |
---|---|---|
20090271708 | Collaboration Software With Real-Time Synchronization - A collaboration program operates on a computer system for storing, sharing and synchronizing data between different users. Centrally stored content data items are organized by associations into one or more folders, with the folders arranged by associations in a multi-level hierarchical structure. Users have access to all folders and content data items falling within at least one top level folder or “file cabinet” viewable by that user. When a user makes a change/addition to the hierarchical structure, that change/addition is transmitted to a server, which makes the change/addition to the necessary associations and sends messages through a TCP/IP format advising other signed-on users of the change/addition. With each content data item having the capability of being associated into multiple folders and each folder having the capability of being associated into multiple other folders or file cabinets, the computer system operating the collaboration program gives different users simultaneous, synchronized access to the folders and content data items in the hierarchical structure. | 10-29-2009 |
20120303716 | Collaboration Software With Real-Time Synchronization - A collaboration program operates on a computer system for storing, sharing and synchronizing data between different users. Centrally stored content data items are organized by associations into one or more folders, with the folders arranged by associations in a multi-level hierarchical structure. Users have access to all folders and content data items falling within at least one top level folder or “file cabinet” viewable by that user. When a user makes a change/addition to the hierarchical structure, that change/addition is transmitted to a server, which makes the change/addition to the necessary associations and sends messages through a TCP/IP format advising other signed-on users of the change/addition. The computer system operating the collaboration program gives different users simultaneous, synchronized access to the folders and content data items in the hierarchical structure. | 11-29-2012 |
Jonathan M. Backer, New Rochelle, NY US
Patent application number | Description | Published |
---|---|---|
20140113869 | Gbetagamma BINDING SITE ON THE PIK3CB GENE PRODUCT AND METHODS OF USE - Methods of treating a disease in a subject are provided comprising administering to the subject an amount of an agent which reduces, or prevents, interaction of a Gβγ with a pi 110β effective to treat the disease. Methods are also provided for identifying an inhibitor of interaction between a Gβγ and a ρ110β. Compositions are provided comprising a peptide comprising amino acid residues having the KAAEIASSDSANVSSRGGKKFLPV (SEQ ID NO:6). | 04-24-2014 |
Joseph M. Backer, W. Simsbury, CT US
Patent application number | Description | Published |
---|---|---|
20080312410 | Cysteine-containing peptide tag for site-specific conjugation of proteins - The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety bound to the targeting moiety; the biological conjugate having a covalent bond between the thiol group of SEQ ID NO:2 and a functional group in the binding moiety. The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety that comprises an adapter protein, the adapter protein having a thiol group; the biological conjugate having a disulfide bond between the thiol group of SEQ ID NO:2 and the thiol group of the adapter protein. The present invention is also directed to biological sequences employed in the above biological conjugates, as well as pharmaceutical preparations and methods using the above biological conjugates. | 12-18-2008 |
20090023649 | Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments - The present invention is directed to an isolated polypeptide including: (1) the A subunit of Shiga-like bacterial toxin, wherein said subunit has the nucleic acid sequence of SEQ ID NO:9; and (2) human vascular endothelial growth factor wherein the growth factor has the nucleic acid sequence of SEQ ID NO:10; wherein the isolated polypeptide possesses ribosome inactivating activity. The present invention is also directed to compositions for inhibiting endothelial cell growth in a patient. | 01-22-2009 |
Joseph M. Backer, Sandy Hook, CT US
Patent application number | Description | Published |
---|---|---|
20100104550 | CLEAVAGE OF BIP BY SUBTILASE CYTOTOXIN - Cleavage of BIP (Immunoglobulin binding protein) by subtilase toxin and its application to inhibiting growth of or killing of cells. This has application to treatment of cancers and to conformational diseases and in particular to conformational diseases involving BiP that are influenced by cleavage by the subtilase cytotoxin. The invention also relates to subtilase toxin molecules specifically targeting proliferating cells, in particular tumor cells, or cells expressing a vascular endothelial growth factor receptor. | 04-29-2010 |
Joshua Backer, Atlanta, GA US
Patent application number | Description | Published |
---|---|---|
20090019060 | CREATING ONLINE SOCIAL LEARNING COMMUNITIES - Distributing knowledge through a learning community includes creating a plurality of learning communities; for each of the plurality of learning communities, allowing creating a knowledge base by the content producers, allowing submitting content to the learning community by the content consumers or the content producers; sharing contents with the content consumers and content producers in many ways. The learning communities are listed in a directory. A category in the directory is able to be drilled into for multiple levels. Each of the multiple levels of the categories in the directory is associated with one or more of the plurality of learning communities. | 01-15-2009 |
Marina V. Backer, W. Simsbury, CT US
Patent application number | Description | Published |
---|---|---|
20080312410 | Cysteine-containing peptide tag for site-specific conjugation of proteins - The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety bound to the targeting moiety; the biological conjugate having a covalent bond between the thiol group of SEQ ID NO:2 and a functional group in the binding moiety. The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety that comprises an adapter protein, the adapter protein having a thiol group; the biological conjugate having a disulfide bond between the thiol group of SEQ ID NO:2 and the thiol group of the adapter protein. The present invention is also directed to biological sequences employed in the above biological conjugates, as well as pharmaceutical preparations and methods using the above biological conjugates. | 12-18-2008 |
20090023649 | Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments - The present invention is directed to an isolated polypeptide including: (1) the A subunit of Shiga-like bacterial toxin, wherein said subunit has the nucleic acid sequence of SEQ ID NO:9; and (2) human vascular endothelial growth factor wherein the growth factor has the nucleic acid sequence of SEQ ID NO:10; wherein the isolated polypeptide possesses ribosome inactivating activity. The present invention is also directed to compositions for inhibiting endothelial cell growth in a patient. | 01-22-2009 |
Marina V. Backer, Sandy Hook, CT US
Patent application number | Description | Published |
---|---|---|
20100104550 | CLEAVAGE OF BIP BY SUBTILASE CYTOTOXIN - Cleavage of BIP (Immunoglobulin binding protein) by subtilase toxin and its application to inhibiting growth of or killing of cells. This has application to treatment of cancers and to conformational diseases and in particular to conformational diseases involving BiP that are influenced by cleavage by the subtilase cytotoxin. The invention also relates to subtilase toxin molecules specifically targeting proliferating cells, in particular tumor cells, or cells expressing a vascular endothelial growth factor receptor. | 04-29-2010 |
Ryan Thomas Backer, Minniapolis, MN US
Scott Backer, Collegeville, PA US
Patent application number | Description | Published |
---|---|---|
20150376116 | VINYL MONOMERS HAVING CHELATING FUNCTIONALITY - The present invention provides novel polymerizable monomers having chelating functionality and processes to make them. In particular, the novel monomers are ethylenically unsaturated aminocarboxylates and are prepared by reacting ethylenediamine triacetic acid or its salt with an ethylenically unsaturated monomer. The ethyleneically unsaturated monomer may be a polymerizable vinyl monomer selected from (o-, p-, m-)DVBMO, allyl glycidyl ether, and glycidyl (meth)acrylate. | 12-31-2015 |
Scott Backer, Philadelphia, PA US
Patent application number | Description | Published |
---|---|---|
20130109823 | POLYMERS HAVING CHELATING FUNCTIONALITY | 05-02-2013 |
20140303337 | POLYMERS HAVING CHELATING FUNCTIONALITY - The present invention provides novel polymers having chelating functionality and comprising units derived from an ethylenically unsaturated aminocarboxylate monomer which comprises units derived from ethylenediamine triacetic acid or its salt and a polymerizable vinyl monomer. The polymerizable vinyl monomer may be selected from (0-, m-, p-)DVBMO, allyl glycidyl ether, and glycidyl (meth)acrylate. The polymer may also comprise units derived from one or more ethylenically unsaturated monomers. | 10-09-2014 |
20140303397 | VINYL MONOMERS HAVING CHELATING FUNCTIONALITY - The present invention provides novel polymerizable monomers having chelating functionality and processes to make them. In particular, the novel monomers are ethylenically unsaturated aminocarboxylates and are prepared by reacting ethylenediamine triacetic acid or its salt with an ethylenically unsaturated monomer. The ethyleneically unsaturated monomer may be a polymerizable vinyl monomer selected from (o-, p-, m-)DVBMO, allyl glycidyl ether, and glycidyl (meth)acrylate. | 10-09-2014 |
20140336410 | ETHYLENICALLY UNSATURATED MONOMERS HAVING CHELATING FUNCTIONALITY - The present invention provides novel polymerizable monomers having chelating functionality and processes to make them. In particular, the novel monomers are vinyl aminocarboxylates and are prepared by reacting iminodiacetic acid, iminodisuccinic acid, or a salt thereof and a vinyl epoxy benzene monomer. | 11-13-2014 |
20150031846 | POLYMERS HAVING CHELATING FUNCTIONALITY - The present invention provides novel polymers having chelating functionality and comprising units derived from a vinyl aminocarboxylate monomer which comprises units derived from iminodiecetic acid, iminodisuccinic acid, or a salt thereof, and a vinyl epoxy benzene monomer. | 01-29-2015 |
Scott Andrew Backer, Philadelphia, PA US
Patent application number | Description | Published |
---|---|---|
20100280281 | ALKOXYLATION OF FLUORINATED ALCOHOLS - A fluorinated alkylalkoxylate, and a process for its preparation in which at least one fluorinated alcohol is contacted with at least one alkylene epoxide in the presence of a catalyst system comprising an alkali metal borohydride, and an organic quaternary salt. | 11-04-2010 |